Q-omics provides the consensus-scored LAMC1 profile across patient tissues and cancer cell-line models. LAMC1 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, LAMC1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, LAMC1 protein abundance shows 23,703 significant protein co-abundance associations, with the highest sampling consensus in COAD. Together, these results highlight BLCA, HNSC, and COAD as cancer lineages where LAMC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LAMC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LAMC1 survival associations across molecular data types. LAMC1 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LAMC1 RNA expression–survival associations across cancer types. High LAMC1 expression shows unfavorable associations in BLCA, UVM, MESO, ACC, STAD and LGG. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for LAMC1 RNA expression.
This table summarizes LAMC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for LAMC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LAMC1 shows lower tumor expression in BRCA and higher tumor expression in HNSC, KIRC, KIRP, LIHC and LUAD. The HNSC box plot shows higher LAMC1 RNA expression in tumor versus normal tissue (log2 FC = +2.513, t-test p < 0.001).
This table shows molecular features associated with LAMC1 in patient tissues and cancer cell lines. In patient samples, LAMC1 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set. In cancer cell lines, LAMC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
